Physician profile
Imad Shawa
NPI 1659341741
$11,129.35
in general payments reported to CMS, 2019-2025
46 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $619 · 2021: $4,468 · 2022: $1,006 · 2023: $1,211 · 2024: $1,327 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,806 · Education: $51.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,805.81 |
| Education | $51.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,400.00 | 2021 | |
| Glaxosmithkline, LLC. | $2,128.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Eli Lilly and Company | $1,200.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $840.47 | 2019-2025 | Ofev, Jascayd |
| Inari Medical, INC. | $471.80 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $439.04 | 2020-2025 | Tezspire, Airsupra, Breztri |
| Amgen INC. | $319.25 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $270.94 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $262.38 | 2020-2024 | Glassia |
| Insmed, INC. | $251.75 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $213.89 | 2019-2025 | Dupixent |
| Ekos Corporation | $200.00 | 2019 | |
| Harmony Biosciences LLC | $196.96 | 2024-2025 | |
| Pfizer INC. | $192.92 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $154.54 | 2021-2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $119.41 | 2019 | |
| Medtronic USA, INC. | $118.19 | 2020 | |
| Medtronic, INC. | $118.16 | 2023 | Solitaire X |
| Baxter Healthcare | $106.75 | 2024-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $105.39 | 2019-2025 | |
| Philips North America LLC | $84.40 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $72.87 | 2020-2022 | |
| Gilead Sciences, INC. | $67.15 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $63.58 | 2019-2025 | Opsumit, Uptravi |
| Arbor Pharmaceuticals, INC. | $62.55 | 2021 | |
| Janssen Pharmaceuticals, INC | $60.49 | 2021-2023 | Xarelto |
| Abiomed | $57.83 | 2025 | |
| Paratek Pharmaceuticals, INC. | $56.91 | 2020-2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $52.55 | 2019-2023 | |
| Genentech USA, INC. | $43.30 | 2019 | |
| Electromed, INC. | $35.16 | 2023-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $33.56 | 2019-2025 | Zerbaxa |
| Ucb, INC. | $31.91 | 2025 | Bimzelx |
| Bayer Healthcare Pharmaceuticals INC. | $31.61 | 2019-2020 | |
| Lungpacer Medical USA INC | $31.09 | 2025 | Aeropace Neurostimulation Console |
| Madrigal Pharmaceuticals | $29.57 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $27.76 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $24.37 | 2025 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $24.16 | 2019 | |
| Shionogi INC | $21.79 | 2023 | Fetroja |
| Csl Behring | $20.99 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $18.47 | 2023 | Arctic Sun 5000 |
| Boston Scientific Corporation | $18.41 | 2019 | |
| Verona Pharma, INC. | $17.56 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $17.19 | 2019 | |
| Masimo Corporation | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Shawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.